维立志博-B(09887):1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告

智通财经
Nov 04

智通财经APP讯,维立志博-B(09887)发布公告,内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情,该等药物的多份研究摘要已被第67届ASH年会收录。其中,1项LBL-034临床研究获选在大会首日作第一个口头报告,展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10